Pfizer, Inc. (PFE) Position Increased by Mizuho Securities USA LLC
Mizuho Securities USA LLC increased its position in shares of Pfizer, Inc. (NYSE:PFE) by 19.5% during the second quarter, according to its most recent 13F filing with the SEC. The fund owned 353,000 shares of the biopharmaceutical company’s stock after buying an additional 57,500 shares during the period. Pfizer makes up 0.6% of Mizuho Securities USA LLC’s portfolio, making the stock its 7th largest position. Mizuho Securities USA LLC’s holdings in Pfizer were worth $11,857,000 at the end of the most recent reporting period.
A number of other large investors also recently made changes to their positions in the stock. Asset Planning Services Ltd. boosted its stake in shares of Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares during the period. D. Scott Neal Inc. boosted its stake in shares of Pfizer by 19.3% in the second quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after buying an additional 504 shares during the period. Orrstown Financial Services Inc. boosted its stake in shares of Pfizer by 23.0% in the first quarter. Orrstown Financial Services Inc. now owns 3,275 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 612 shares during the period. Franklin Parlapiano Turner & Welch LLC bought a new stake in shares of Pfizer during the first quarter worth approximately $121,000. Finally, Cascade Investment Advisors Inc. boosted its stake in shares of Pfizer by 89.1% in the second quarter. Cascade Investment Advisors Inc. now owns 4,669 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 2,200 shares during the period. Hedge funds and other institutional investors own 69.09% of the company’s stock.
Pfizer, Inc. (PFE) traded up 0.12% on Friday, reaching $33.96. The company’s stock had a trading volume of 18,179,055 shares. The company has a market capitalization of $201.97 billion, a price-to-earnings ratio of 24.84 and a beta of 1.00. The stock has a 50 day moving average price of $33.30 and a 200-day moving average price of $33.47. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $34.99.
Pfizer (NYSE:PFE) last released its quarterly earnings data on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.65 by $0.02. Pfizer had a net margin of 15.84% and a return on equity of 24.51%. The business had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the previous year, the business earned $0.64 EPS. Pfizer’s quarterly revenue was down 1.9% compared to the same quarter last year. Equities analysts predict that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.
The firm also recently disclosed a quarterly dividend, which was paid on Friday, September 1st. Investors of record on Friday, August 4th were paid a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 3.77%. The ex-dividend date was Wednesday, August 2nd. Pfizer’s payout ratio is presently 94.12%.
COPYRIGHT VIOLATION WARNING: “Pfizer, Inc. (PFE) Position Increased by Mizuho Securities USA LLC” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this story on another site, it was illegally copied and reposted in violation of United States & international copyright and trademark laws. The original version of this story can be accessed at https://www.watchlistnews.com/pfizer-inc-pfe-position-increased-by-mizuho-securities-usa-llc/1538440.html.
A number of brokerages have weighed in on PFE. Citigroup Inc. lowered Pfizer from a “neutral” rating to a “sell” rating and reduced their price target for the stock from $38.00 to $31.00 in a research note on Tuesday, May 16th. BidaskClub raised Pfizer from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 5th. Jefferies Group LLC set a $35.00 price target on Pfizer and gave the stock a “neutral” rating in a research note on Wednesday, August 2nd. BMO Capital Markets raised Pfizer from a “market perform” rating to an “outperform” rating and increased their price target for the stock from $33.00 to $37.00 in a research note on Wednesday, August 2nd. Finally, Credit Suisse Group lowered Pfizer from an “outperform” rating to a “neutral” rating and reduced their price target for the stock from $38.00 to $36.00 in a research note on Thursday, July 20th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average target price of $37.61.
In related news, CEO Ian C. Read sold 197,168 shares of Pfizer stock in a transaction on Thursday, August 31st. The shares were sold at an average price of $34.00, for a total value of $6,703,712.00. Following the completion of the sale, the chief executive officer now owns 580,318 shares of the company’s stock, valued at approximately $19,730,812. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of Pfizer stock in a transaction on Monday, August 7th. The shares were sold at an average price of $33.50, for a total transaction of $502,500.00. Following the completion of the sale, the insider now directly owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. In the last ninety days, insiders sold 418,941 shares of company stock valued at $14,226,011. 0.06% of the stock is owned by company insiders.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.